Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

被引：0

作者：

Nathwani, Nitya ^{[1
]}

Krishnan, Amrita Y. ^{[1
]}

Richardson, Paul G. ^{[2
]}

机构：

[1] City Hope Canc Ctr, Judy & Bernard Briskin Ctr Myeloma, Duarte, CA 91010 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

ONCOLOGY-NEW YORK | 2016年 / 30卷 / 08期

关键词：

LENALIDOMIDE; MULTICENTER; MAINTENANCE; THERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：747 / 749

页数：3

共 15 条

[1]

Attal M, 2015, BLOOD, V126, P391, DOI DOI 10.1182/BLOOD.V126.23.391.391

[2]

Attal M, 2015, BLOOD, V126

[3]

Avet-Loiseau H., 2015, Blood, V126, P191, DOI DOI 10.1182/BLOOD.V126.23.191.191

[4] Darwinian evolution and tiding clones in multiple myeloma [J].

Bahlis, Nizar J. .

BLOOD, 2012, 120 (05) :927-928

[5] Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 [J].

Durie, Brian ;

Hoering, Antje ;

Rajkumar, S. Vincent ;

Abidi, Muneer H. ;

Epstein, Joshua ;

Kahanic, Stephen P. ;

Thakuri, Mohan C. ;

Reu, Frederic J. ;

Reynolds, Christopher M. ;

Sexton, Rachael ;

Orlowski, Robert Z. ;

Barlogie, Bart ;

Dispenzieri, Angela .

BLOOD, 2015, 126 (23)

[6] Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial [J].

Gay, Francesca ;

Oliva, Stefania ;

Petrucci, Maria Teresa ;

Conticello, Concetta ;

Catalano, Lucio ;

Corradini, Paolo ;

Siniscalchi, Agostina ;

Magarotto, Valeria ;

Pour, Ludek ;

Carella, Angelo ;

Malfitano, Alessandra ;

Petro, Daniela ;

Evangelista, Andrea ;

Spada, Stefano ;

Pescosta, Norbert ;

Omede, Paola ;

Campbell, Philip ;

Liberati, Anna Marina ;

Offidani, Massimo ;

Ria, Roberto ;

Pulini, Stefano ;

Patriarca, Francesca ;

Hajek, Roman ;

Spencer, Andrew ;

Boccadoro, Mario ;

Palumbo, Antonio .

LANCET ONCOLOGY, 2015, 16 (16) :1617-1629

[7]

Health Resources and Services Administration

[8]

US Department of Health and Human Services, US TRANSPL DAT DIS R

[9] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].

Kumar, S. K. ;

Lee, J. H. ;

Lahuerta, J. J. ;

Morgan, G. ;

Richardson, P. G. ;

Crowley, J. ;

Haessler, J. ;

Feather, J. ;

Hoering, A. ;

Moreau, P. ;

LeLeu, X. ;

Hulin, C. ;

Klein, S. K. ;

Sonneveld, P. ;

Siegel, D. ;

Blade, J. ;

Goldschmidt, H. ;

Jagannath, S. ;

Miguel, J. S. ;

Orlowski, R. ;

Palumbo, A. ;

Sezer, O. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2012, 26 (01) :149-157

[10] Daratumumab granted breakthrough drug status [J].

Laubach, Jacob P. ;

Tai, Yu-Tzu ;

Richardson, Paul G. ;

Anderson, Kenneth C. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (04) :445-452

← 1 2 →